Michelle Khoo, MD
Cardiovascular Disease · Decatur, TXNPI 1245267236
Payments from drug & device makers
Across 724 payments — averaging $93.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$48K
- Abbott$8K
- E.r. Squibb & Sons, L.L.C.$3K
- Novartis$1K
- Johnson & Johnson$1K
- Boston Scientific$1K
- plus $5K from 25 others
What the payments were for
- Consulting fees$2,9004%
- Speaking & faculty fees$41,50061%
- Travel & lodging$6,2119%
- Food & beverage$17,21025%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 136 | $48,096 |
| Abbott | 131 | $7,957 |
| E.r. Squibb & Sons, L.L.C. | 22 | $3,205 |
| Novartis | 99 | $1,118 |
| Johnson & Johnson | 76 | $1,044 |
| Boston Scientific | 46 | $1,003 |
| Boehringer Ingelheim | 62 | $927 |
| Atricure, Inc. | 8 | $919 |
| Merck | 36 | $486 |
| Inspire Medical Systems, Inc. | 8 | $463 |
| AstraZeneca | 20 | $391 |
| Pfizer | 29 | $390 |
| Medtronic | 5 | $344 |
| Novo Nordisk | 12 | $292 |
| Abiomed | 2 | $173 |
| Lilly USA, LLC | 2 | $167 |
| Axonics, Inc. | 2 | $153 |
| Sanofi-aventis U.S. LLC | 7 | $143 |
| Bayer | 1 | $125 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 1 | $90 |
| Kestra Medical Technology Services, Inc. | 2 | $74 |
| Amarin Pharma, Inc. | 4 | $52 |
| Amgen | 4 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $42 |
| Shield Therapeutics Inc | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Irhythm Technologies, Inc. | 1 | $22 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Baxter Healthcare | 1 | $16 |
| Altathera Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$45,134
- CAMZYOS$2,900
- AVEIR$1,861
- HeartMate 3 Left Ventricular Dev$808
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$589
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$414
- SYNERGY ABLATION SYSTEM$340
- Micra$301
- Advisor Catheter$281
- HeartMate 3 Left Ventricular Assist Device$245
- Inspire$244
- Quadra Assura CRT Defibrillator$200
- ENSITE$177
- Accent Pacemaker$164
- QUADRA ALLURE MP$154
- Axonics$137
- Kerendia$125
- Ozempic$113
- MOUNJARO$110
- Fortify Assura, Ellipse ICD$109
How this compares
$67,842 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 229 | $226,123 |
| XareltoRivaroxaban | 89 | $84,842 |
| EntrestoSacubitril/Valsartan | 53 | $68,065 |
| JardianceEmpagliflozin | 48 | $53,747 |
| BrilintaTicagrelor | 40 | $24,815 |
| FarxigaDapagliflozin Propanediol | 30 | $24,600 |
| Flecainide Acetate | 99 | $4,066 |
| Metoprolol Succinate | 286 | $4,014 |
| Rosuvastatin Calcium | 120 | $1,756 |
| Atorvastatin Calcium | 202 | $1,699 |
| Amiodarone Hcl | 79 | $1,484 |
| Carvedilol | 177 | $1,345 |
| ClopidogrelClopidogrel Bisulfate | 129 | $1,176 |
| Midodrine Hcl | 13 | $1,133 |
| Lisinopril | 103 | $998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $390 | $226,123229 claims |
| Johnson & JohnsonXarelto | $1,044 | $84,84289 claims |
| NovartisEntresto | $1,118 | $68,06553 claims |
| Boehringer IngelheimJardiance | $927 | $53,74748 claims |
| AstraZenecaBrilinta, Farxiga | $391 | $49,41570 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Decatur
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.